(Q38093128)

English

Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer

scientific article published on April 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1

object named as

Sohita Dhillon

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

73

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

475-485

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Targeting hypoxia and angiogenesis through HIF-1alpha inhibition.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

The tumor microenvironment and its contribution to tumor evolution toward metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Clinical pharmacokinetics of everolimus

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

1st International consensus guidelines for advanced breast cancer (ABC 1).

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0034-2

21 January 2018

Reversing hormone resistance: have we found the golden key?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23529824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mammalian target of rapamycin: a central node of complex signaling cascades

1 reference

https://pubmed.ncbi.nlm.nih.gov/23529824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Breast Cancer: Blocking both driver and escape pathways improves outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/23529824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23529824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40265-013-0034-2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38093128&oldid=2201261016"